Low-dose memantine attenuated methadone dose in opioid-dependent patients: a 12-week double-blind randomized controlled trial

Sheng-Yu Lee1,2,*, Shiou-Lan Chen2,3,*, Yun-Hsuan Chang4, Po See Chen2, San-Yuan Huang5, Nian-Sheng Tzeng5, Liang-Jen Wang6, I Hui Lee7, Tzu-Yun Wang6, Kao Chin Chen2, Yen Kuang Yang2, Jau-Shyong Hong7 & Ru-Band Lu2,4,8,9,10

Low-dose memantine might have anti-inflammatory and neurotrophic effects mechanistically remote from an NMDA receptor. We investigated whether add-on memantine reduced cytokine levels and benefitted patients with opioid dependence undergoing methadone maintenance therapy (MMT) in a randomized, double-blind, controlled 12-week study. Patients were randomly assigned to a group: Memantine (5 mg/day) (n = 53) or Placebo (n = 75). The methadone dose required and retention in treatment were monitored. Plasma tumor necrosis factor (TNF)-α, C-reactive protein (CRP), interleukin (IL)-6, IL-8, transforming growth factor (TGF)-β1, and brain-derived neurotrophic factor (BDNF) levels were examined during weeks 0, 1, 4, 8, and 12. General linear mixed models were used to examine therapeutic effect. After 12 weeks, Memantine-group required a somewhat lower methadone dose than did Placebo-group (P = 0.039). They also had significantly lower plasma TNF-α and significantly higher TGF-β1 levels. We provide evidence of the benefit of add-on memantine in opioid dependent patients undergoing MMT.

Opioid dependence is often characterized by repetitive drug-seeking and drug-taking behaviors with severe public health consequences. Current efforts to taper individuals off opioids often lead to limited results because of a high relapse rate and troublesome subjective symptoms. Although methadone maintenance therapy (MMT) has been suggested as effective for opioid dependence1, after methadone is discontinued, the opioid dependents often relapse. Using MMT alone may not be sufficient for treating opioid dependence. Therefore, there is a need to develop adjuvant therapeutic interventions for opioid-dependent patients during long-term MMT.
Opioids cause oxidative stress and inflammatory responses. Evidence from human and animal studies in vivo and in vitro suggest that opioid abuse may have adverse immunomodulatory effects on innate and adaptive immune responses. In vitro studies report that acute morphine treatment alters the production of various cytokines, including tumor necrosis factor (TNF)-α and IL-6. In the brains of opioid-dependent patients, higher cytokine expression levels were detected in noradrenergic locus coeruleus cells. Chronic heroin use has been associated with decreased serum concentrations of nerve growth factor and brain-derived neurotrophic factor (BDNF). Another study showed that the increase of BDNF in the nucleus accumbens was closely related to dependence on cocaine and other drugs, and to dependency relapse. In addition, BDNF is involved in long-term behavioral adaptation induced by drug dependence.

Current treatment for opioid dependence in practice remains less than ideal. Although agonist maintenance using methadone or buprenorphine remains the treatment of choice, using these agonists to treat young people, newly diagnosed patients, or abusers of prescribed opioids remains controversial. MMT is sometimes not available or acceptable to many patients, nor is it universally effective. Because inflammation and neurodegeneration have been reported in the progression of opioid dependence, treatment combining anti-inflammatory and neuroprotective agents may provide more benefit than current management without these agents. We recently showed that using low-dose (0.02 mg/kg) memantine, an N-methyl-D-aspartate (NMDA) receptor antagonist, abolished morphine-induced conditioned-place-preference behavior in rats because of its IL-6-modulating effect in the medial prefrontal cortex. Our preliminary clinical data also showed that low-dose memantine added to valproate given to patients with bipolar II disorder significantly attenuated plasma cytokines. We hypothesized that a low dose of add-on memantine would therapeutically benefit opioid-dependent patients. We conducted a double-blind, placebo-controlled study of add-on low-dose memantine (5 mg/day) in opioid-dependent patients undergoing MMT to evaluate whether memantine would reduce the dose of methadone needed.

Methods
Study design. The research protocol was approved by the Institutional Review Board for the Protection of Human Subjects at National Cheng Kung University Hospital, and the methods were carried out in accordance with the approved guidelines. After the study had been completely described to the participants, they all signed written informed consent forms.

Opioid-dependent patients were recruited from the MMT program. None of the patients received methadone prior to this trial; all patients were newly inducted onto methadone. Each participant was initially interviewed and evaluated by an attending psychiatrist, and then the evaluation was confirmed by a research team member well-trained and experienced in using the Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) criteria and the Chinese Version of the Mini International Neuropsychiatric Interview (MINI). Inclusion criteria were men and women between 18 and 65 years old who met the DSM-IV criteria for current opioid dependence and who used opioids daily. Exclusion criteria were a major or minor mental illness other than opioid dependency, antisocial personality disorder, and cognitive disorders. Other exclusion criteria were being pregnant or nursing an infant, having taken any anti-inflammatory medications within 1 week before the study, or having a history of one or more uncontrolled major physical conditions such as chronic diabetes mellitus or chronic hypertension.

Procedures. Participants were randomly assigned to one of two groups: Placebo (taking methadone + one daily placebo capsule) or Memantine (taking methadone + one daily 5-mg memantine sustained-release capsule) for 12 weeks. The randomization strategy for treatment was simple randomization using excel’s random number generator. Methadone maintenance treatment was launched in Taiwan by the government in 2006 and made available countrywide for treatment of opioid dependence in Taiwan since 2007. The guideline in Taiwan from Department of Health suggested an initial dosage range of 10–40 mg per day, but preferably not over 30 mg/day. An increase or decreased by 5 mg increment according to clinician’s evaluation, patients’ subjective responses including withdrawal symptoms and tolerance to methadone. The primary outcome of the study was to compare the methadone dose required, retention rates, and concomitant opioid use of participants in the 12-week trial. The methadone doses required were recorded at baseline and on day 7 of weeks 1, 4, 8, and 12. The secondary outcome of the study was to compare the immunological parameters including TNF-α, CRP, IL-6, IL-8, and TGF-β1 levels and plasma BDNF levels at baseline and on day 7 of weeks 1, 4, 8, and 12. All patients received evaluation of sections of Opiate Treatment Index (OTI) including drug use, criminality, and health at endpoint as behavioral measures and side effect checklist for adverse event.

Outcome Measurement. The dose used in the current study was determined from animal and human studies of addiction behavior. In an animal study, we found that using a low dose of memantine (0.2–1 mg/kg/day) abolished morphine-induced conditioned place preference behavior in rats because of its anti-inflammatory and neurotrophic effects in the addiction-related brain area. We converted that to...
a human-equivalent dose (0.03–0.16 mg/kg) (U.S. Department of Health and Human Services, 2005). By assuming the average human weight to be 60 kg, we determined that the median daily dose for humans is 5 mg (range: 1.8–9.6 mg/day). We have also used add-on oral memantine (5 mg/day) with valproic acid (VPA) to treat patients with bipolar II disorder. We found that although add-on memantine + VPA may not be more effective for clinical symptoms than was placebo + VPA, memantine may have improved plasma TNF-α levels, but that it had little effect on other cytokines. We therefore used this dose to treat heroin-dependent patients.

Ten milliliters of whole blood was withdrawn from the antecubital vein of each patient at baseline and on day 7 of weeks 1, 4, 8, and 12. Plasma, which was isolated from the whole blood after it had been centrifuged at 3000g for 15 min at 4°C, was immediately stored at −80°C. Cytokine levels were quantified using an antibody pair assay system (Flexia; BioSource Intl., Camarillo, CA). A BDNF kit (Quantikine Human BDNF kit; R&D Systems, Minneapolis, MN) and an enzyme-linked immunosorbent assay (ELISA) reader (SpectraMax-M2; Molecular Devices, Sunnyvale, CA) were used to analyze the plasma BDNF level. Samples were processed and data analyzed according to the manufacturer’s instructions. The immunological parameters (TNF-α, CRP, IL-6, IL-8, and TGF-β1) and BDNF were assessed.

Statistical Analyses. The demographic and clinical characteristics of the patients and their baseline methadone dose, cytokine levels, and BDNF levels were compared between groups using one-way analysis of variance (ANOVA) for continuous variables and χ² tests for categorical variables. The randomization strategy for treatment was simple randomization using excel's random number generator. Data are means ± standard deviation (SD). Arithmetic transformations were used to produce approximately normal distributions for further analysis; log (x + 1) was used for cytokine levels. Potential prognostic factors included the treatment duration (0–12 weeks), memantine dose, gender, and age. Because there were repeated assessments, mixed-effect-model analysis was used to control for time effects, age, and gender, and used on longitudinal outcomes (methadone doses, cytokine levels, and BDNF levels) to evaluate the possible effects of the prognostic factors on the response values. We used mixed-effect models to analyze the effect of add-on placebo and memantine during 12 weeks treatment in opioid-dependent participants. A total of 8 models ran with each outcome as a dependent variable. In each model, treatment received (memantine vs. controls), treatment course, treatment received X treatment course, gender, and age were included as independent variables. The covariance structure employed was compound symmetry model. The placebo group was used as reference group. The interaction term of treatment received and treatment duration was regarded as effect of add-on memantine. The retention rate was estimated using the Kaplan-Meier product limit estimate method, and survival curves for the two groups were compared using the Wilcoxon rank sum test. SPSS 18.0 for Windows was used for statistical computations. Significance was set at p < 0.05.

Results
Study Participants. One hundred eighty opioid-dependent patients were screened for eligibility (See Fig. 1 for the CONSORT Flow Diagram). Forty-six of those screened declined to participate (failed to complete the evaluation and were not interested in treatment other than methadone). Finally, 134 patients were randomized to memantine group (n = 53) or placebo group (n = 75). The CONSORT diagram is shown in Figure 1.
opioid-dependent participants entered the study and underwent randomization, however, 4 patients in the Memantine group and 2 patients in the Placebo group failed to enter the trial after screening. The rest patients were randomly assigned to the Memantine group (n = 53) or the Placebo group (n = 75) for 12 weeks. One hundred three (80.5%) of the 128 patients completed the double-blind phase, and 25 (19.5%) dropped out (Placebo: n = 17; 22.7%; Memantine: n = 8; 15.1%). Their reasons for discontinuing the study were as follows: Loss of follow-up for an unknown reason (Placebo: n = 10; Memantine: n = 2), refused treatment (Placebo: n = 2; Memantine: n = 5), violation of protocol (Placebo: n = 3; Memantine: n = 1), and incarcerated in prison during treatment (Placebo: n = 2; Memantine: n = 0). No adverse events were reported in either treatment group.

Primary and Secondary Outcomes. The demographic and clinical characteristics, baseline methadone dose scores, and BDNF and cytokine levels of the patients were similar in both patient groups at baseline, but all cytokine levels were distributed erratically and showed a significant level of positive skew.

### Table 1. Baseline and endpoint characteristics of opioid-dependent patients taking memantine or a placebo.

| Characteristics                          | Baseline Mean ± SD | p-value | Endpoint Mean ± SD | p-value |
|------------------------------------------|--------------------|---------|--------------------|---------|
| **Demographic data**                    |                    |         |                    |         |
| Gender (male/female) (n)                 | Memantine 43/10    | 0.813   | Placebo 63/12      | 0.923   |
| Age (years) (mean ± SD)                  | Memantine 37.06 ± 6.97 | 0.465 | Placebo 36.93 ± 7.15 | 0.839 |
| Year of Heroin Use (mean ± SD)           | Memantine 8.48 ± 7.10 | 0.465 | Placebo 7.58 ± 6.44 | 0.357   |
| History of alcohol abuse (yes/no) (n)  | Memantine 13/40     | 0.329   | Placebo 25/50      | 0.329   |
| Year of amphetamine used (mean ± SD)     | Memantine 1.57 ± 1.07| 0.080   | Placebo 2.72 ± 3.68| 0.080   |

| Primary Outcome                          |                    |         |                    |         |
| Methadone dose (mg) (mean ± SD)          | Memantine 34.32 ± 20.00 | 0.655 | Placebo 36.07 ± 22.90 | 0.655   |

| Secondary Outcome                        |                    |         |                    |         |
| TNF-α (pg/mL) (mean ± SD)                | Memantine 3.65 ± 2.67 | 0.824   | Placebo 3.77 ± 3.30 | 0.824   |
| CRP (ng/mL) (mean ± SD)                  | Memantine 3802.00 ± 2929 | 0.956 | Placebo 3933.00 ± 3164 | 0.956   |
| IL-6 (pg/mL) (mean ± SD)                 | Memantine 2.40 ± 2.16 | 0.833   | Placebo 2.49 ± 2.56 | 0.833   |
| IL-8 (pg/mL) (mean ± SD)                 | Memantine 6.22 ± 9.77 | 0.351   | Placebo 5.01 ± 4.50 | 0.351   |
| TGF-β1 (ng/mL) (mean ± SD)               | Memantine 23.12 ± 15.69 | 0.860 | Placebo 23.62 ± 15.70 | 0.860   |
| BDNF (ng/mL) (mean ± SD)                 | Memantine 9.08 ± 6.11 | 0.098   | Placebo 11.35 ± 8.49 | 0.098   |

| Opiate treatment index (OTI)              |                    |         |                    |         |
| Drug use                                  |                    |         |                    |         |
| Heroin use (mean ± SD)                    | Memantine 1.02 ± 1.33 | 0.19    | Placebo 1.41 ± 1.78 | 0.19    |
| Amphetamine use (mean ± SD)               | Memantine 0.44 ± 2.77 | 0.37    | Placebo 0.14 ± 0.55 | 0.37    |
| Tobacco use (mean ± SD)                   | Memantine 19.75 ± 10.42 | 0.62   | Placebo 20.66 ± 9.70 | 0.62   |
| Criminality (mean ± SD)                   | Memantine 0 ± 0      | 0.40    | Placebo 0.03 ± 0.234| 0.40    |
| Health (mean ± SD)                        | Memantine 5.52 ± 3.83 | 0.69    | Placebo 5.82 ± 4.38 | 0.69    |

VPA: valproate; HDRS: Hamilton Depression Rating Scale; YMRS: Young Mania Rating Scale; TNF-α: tumor necrosis factor-α; IL-6: interleukin 6; IL-8: interleukin 8; IL-1β: interleukin 1β. 1Heroin use (number of injections on the day of use) 2Amphetamine use (number of snorts on the day of use) 3Tobacco use (number of cigarette on the day of use) 4Criminality: number of crime offended in four crime areas: property crime, dealing, fraud, and crimes involving violence. 5Health: The higher the score, the poorer the overall health of the subject.
There were no significant behavioral differences in drug use, criminality nor physical health in OTI between the Memantine and Placebo groups before or after 12 weeks treatment (Table 1). Past amount of heroin use was not recorded because the purity of heroin varies widely. None of the patients received methadone or other opioid agonists prior to this trial; all patients were newly inducted onto methadone since methadone was launched in Taiwan by the government in 2006 and made available countrywide for treatment of opioid dependence in Taiwan since 2007.

The data presented in Table 2 was the main effect (treatment received, treatment course, gender, and age) and interaction term (treatment received X treatment course) from each model (using each outcome as dependent variable). The change in the required methadone dose and its normalization against the baseline dose (week 0 = 100%) after 12 weeks of treatment in the two groups are plotted in Figs. 2, 3. The required methadone dose in the Memantine group was significantly lower both before (p = 0.034) and after normalization (p = 0.025) (Figs. 1, 2; Table 2). Our finding suggests that those treated with 5 milligram of memantine, the required methadone dose decreased by 0.948 mg over each visit compared to Placebo group when controlling for the effects of gender and age. The Memantine group had a significantly lower TNF-α level (p = 0.004) and a significantly higher TGF-β level (p = 0.017) than did the Placebo group, but BDNF and other cytokine levels were not significantly different. There are also several significant main effects of age, gender or treatment course in the models analyzed in Table 2. However, these significant model main effects do not affect the outcome or do not represent effect of add-on memantine. If we control for baseline methadone dose, the required methadone dose decreased by 0.950 mg over each visit (P = 0.032) compared to the placebo group when controlling for the effects of gender and age.

There were no significant differences in retention rates between the Memantine and Placebo groups (Table 3). As for adverse effect, no significant differences were found between the Memantine and Placebo groups (Table 4). However, marginally more adverse symptoms in urogenital system were found in Memantine group compared to Placebo group (P = 0.07).

Discussion

There are no published reports that both evaluate add-on low-dose memantine used to treat opioid-dependent patients undergoing MMT and closely monitor patient cytokine levels during treatment. We found that add-on memantine was significantly more effective than placebo for decreasing dose of methadone required. We also found that add-on memantine plus methadone was significantly more effective than methadone alone for decreasing TNF-α levels and increasing TGF-β levels, but not for modulating CRP, IL-6, IL-8, or BDNF levels for opioid-dependent patients. However, the difference in increase of the TGF-β levels appears to be because the levels in Placebo group dropped but not increase in Memantine group. Although no significant differences in side effect was found between Memantine and Placebo groups, marginally more adverse symptoms in urogenital system were found in Memantine group (P = 0.07). Our study provides initial evidence that memantine may be effective for reducing the patient's methadone dose required and decreasing some inflammatory factors in opioid-dependent patients.

The main finding of the current study, difference in methadone dosage, was only significant after considering effect of time using mixed model analysis. At endpoint, only borderline difference in methadone dosage between memantine and control groups was seen (Table 1). In other words, current study demonstrated the effect of memantine compared to placebo as 1 mg vs. 8 mg increase in methadone dose required. Methadone maintenance treatment was launched in Taiwan by the government in 2006 and made available countrywide in 2007. One recent study comprised of a cohort of 33,549 patients recruited from 2006 to 2008 reported that over half over patients received methadone less than 45 mg per day and the mean dose was 46.5 ± 20.9 mg/day, while average treatment duration was 171.5 days. The average dose reported by Liao et al. is similar to the endpoint dose in the Placebo group in the current study. On the other hand, the guideline in Taiwan suggests an increment of 5 mg of methadone a day for dose adjustment. Therefore, our finding suggests that add-on memantine may decrease methadone dose needed by about 2 increment levels compared to national average dosage. However, lacking of any behavioral or craving or self-administration data, the clinical relevance of our finding still requires further study. Furthermore, due to lower average dose and shorter clinical experience of methadone in Taiwan compared to that in the U.S., the result of the current study may not be applicable to other countries or ethnicities.

Heroin-dependent patients may develop a tolerance for methadone. However, we found that, after 12 weeks of MMT plus add-on low-dose memantine, the dose of methadone required by Memantine-group patients was significantly lower than the dose required by Placebo-group patients. Because the retention rate (which indicates a craving for heroin) did not differ between the two study groups, our results support the notion that a reduction in the required dose of methadone indicates that the patient's tolerance to methadone has been inhibited and that the patient's symptoms when withdrawing from heroin will be less severe. In clinical practice, patients who abuse opioids may continue MMT for years. Although methadone tolerance has not yet been reported in Han Chinese people, it is an important issue that needs to be addressed and managed. In addition, methadone is neurotoxic: chronic methadone use might damage the striatal dopamine transporter in humans and impair cognitive function and sustained attention. Thus, patients undergoing long-term MMT might experience more brain dysfunction and structural impairment. We hypothesize that MMT plus add-on low-dose memantine will not only reduce...
| Parameter                                                                 | Covariant                     | Estimate | SE  | t    | p-value   | AIC  |
|--------------------------------------------------------------------------|-------------------------------|----------|-----|------|-----------|------|
| **Primary Outcome**                                                      |                               |          |     |      |           |      |
| Methadone dose required<sup>1,2</sup>                                    | Treatment received X         | −0.948   | 0.446 | −2.128 | 0.034*    | 5709.7 |
|                                                                           | Treatment course              | 0.135    | 3.957 | 0.034 | 0.973     |      |
|                                                                           | Treatment course              | 1.307    | 0.291 | 4.488 | <0.001    |      |
|                                                                           | Age                           | −0.904   | 0.273 | −3.303 | 0.001     |      |
|                                                                           | Gender                        | −0.068   | 5.099 | −0.013 | 0.989     |      |
| % of change from baseline in methadone dose required<sup>1</sup>          | Treatment received X         | −0.031   | 0.014 | −2.242 | 0.025*    |      |
|                                                                           | Treatment course              | 0.044    | 0.059 | 0.749 | 0.454     | 497.0 |
|                                                                           | Treatment course              | 0.051    | 0.009 | 5.545 | <0.001    |      |
|                                                                           | Age                           | 0.004    | 0.003 | 1.630 | 0.106     |      |
|                                                                           | Gender                        | −0.071   | 0.051 | −1.392 | 0.166     |      |
| **Secondary Outcome**                                                    |                               |          |     |      |           |      |
| TNF-α (pg/mL)                                                            | Treatment received X         | −0.035   | 0.012 | −2.924 | 0.004<sup>**</sup> | 300.4 |
|                                                                           | Treatment course              | 0.078    | 0.070 | 1.117 | 0.265     |      |
|                                                                           | Treatment course              | 0.003    | 0.008 | 0.425 | 0.671     |      |
|                                                                           | Age                           | 0.004    | 0.004 | 1.099 | 0.315     |      |
|                                                                           | Gender                        | −0.045   | 0.079 | −0.567 | 0.572     |      |
| CRP (pg/mL)                                                              | Treatment received X         | −0.017   | 0.010 | −1.630 | 0.104     | 228.0 |
|                                                                           | Treatment course              | 0.016    | 0.077 | 0.213 | 0.832     |      |
|                                                                           | Treatment course              | −0.014   | 0.007 | −2.055 | 0.040     |      |
|                                                                           | Age                           | −0.002   | 0.005 | −0.378 | 0.706     |      |
|                                                                           | Gender                        | −0.045   | 0.096 | −0.475 | 0.636     |      |
| IL-6 (pg/mL)<sup>2</sup>                                                 | Treatment received X         | 0.003    | 0.010 | 0.283 | 0.777     | 181.4 |
|                                                                           | Treatment course              | −0.007   | 0.064 | −0.114 | 0.909     |      |
|                                                                           | Treatment course              | −0.016   | 0.007 | −2.351 | 0.019     |      |
|                                                                           | Age                           | 0.007    | 0.004 | 1.657 | 0.100     |      |
|                                                                           | Gender                        | −0.131   | 0.076 | −1.733 | 0.085     |      |
| IL-8 (pg/mL)                                                             | Treatment received X         | −0.016   | 0.017 | −0.921 | 0.357     | 655.0 |
|                                                                           | Treatment course              | 0.092    | 0.091 | 1.014 | 0.312     |      |
|                                                                           | Treatment course              | −0.032   | 0.011 | −2.923 | 0.004     |      |
|                                                                           | Age                           | 0.002    | 0.015 | 0.430 | 0.668     |      |
|                                                                           | Gender                        | 0.019    | 0.099 | 0.190 | 0.850     |      |
| TGF-β1 (pg/mL)                                                           | Treatment received X         | 0.028    | 0.012 | 2.403 | 0.017<sup>**</sup> | 231.7 |
|                                                                           | Treatment course              | −0.057   | 0.058 | −0.997 | 0.319     |      |
|                                                                           | Treatment course              | −0.016   | 0.008 | −2.077 | 0.038     |      |
|                                                                           | Age                           | −0.010   | 0.003 | −3.219 | 0.002     |      |
|                                                                           | Gender                        | 0.114    | 0.059 | 1.915 | 0.058     |      |

Continued
Table 2. Effect of memantine vs. placebo during 12 weeks of treatment on primary and secondary outcomes in heroin-dependent patients. SE: Standard Error; TNF-α: tumor necrosis factor-α; CRP: C-reactive protein; IL-6: interleukin 6; IL-8: interleukin 8; TGF-β1: transforming growth factor β1; BDNF: brain-derived neurotrophic factor. Primary outcomes and secondary outcomes are dependent variables. Independent variable shown here is the interaction of treatment received and treatment course. Other covariables are treatment received, treatment course, gender, age. Reference group is Placebo group. *p < 0.05, **p < 0.01

Figure 2. Change in the mean dose of oral methadone in the Memantine and Placebo groups after 12 weeks of treatment.

Figure 3. The mean proportion of change in the oral dose of methadone, normalized using the baseline data (week 0 = 100%) of each patient in the Memantine and Placebo groups after 12 weeks of treatment.
tolerance to methadone and shorten the time for efficacious MMT, but also reduce neuronal damage caused by methadone. These proposed effects of memantine may require further data such as opioid withdrawal measures, opioid craving measures, and neurocognitive function evaluation to confirm.

We found that add-on low-dose memantine was beneficial for attenuating plasma TNF-α levels in opioid-dependent patients. However, a longer follow-up period (i.e., at least 6 months) is necessary in future experiments to confirm our finding. We also found initial evidence of significant difference in the plasma TGF-β levels in the two treatment groups, considering the difference in increase of the TGF-β levels appears to be because the levels in Placebo group dropped. The TGF-β1 is a potent anti-inflammatory cytokine that regulates various physiological processes, viz., cell proliferation, cell differentiation, and extracellular matrix synthesis, and that inhibits cellular and humoral immune responses and cytokine production. Furthermore, TGF-β1 induces plasminogen activator inhibitor 1 (PAI-1) synthesis and stimulates the synthesis of collagen and α-actin in vascular smooth muscle cells. Therefore, TGF-β1 has been implicated in the pathogenesis of autoimmune disease, carcinogenesis, and cardiovascular disease. Evidence indicates that TGF-β is implicated in cardiovascular disease with significantly higher plasma levels of activated TGF-β in patients with coronary heart disease. We hypothesize that memantine increased the activation of the immune response to heroin and methadone use by maintaining the plasma TGF-β1 levels. However, whether this is, in fact, the mechanism must be confirmed in future studies.

Studies on memantine’s therapeutic effect on opioid dependence are scarce, and those that do exist have small study populations and controversial findings. When used alone at higher doses (30 or 60 mg/day), memantine attenuated the symptoms of opioid withdrawal and modestly reduced the craving for heroin. As an adjunct (30 or 60 mg/day) to oral naltrexone in a more recent clinical study, however, memantine did not increase treatment retention or mitigate the symptoms of opioid withdrawal or heroin craving. Clinical studies of memantine’s therapeutic effects for other types of substance dependence—alcohol, cocaine, and nicotine—are contradictory and mostly negative. Other researchers have attributed memantine’s beneficial effects against substance abuse to its NMDA blocker effect. In the current study, patients were given only 5 mg of memantine per day, and their plasma memantine concentration was about 10–50 ng/ml (0.05–0.2 μM). Such a low dose of plasma memantine was not high enough to block the NMDA receptors (50% inhibition concentration [IC50] of memantine: 2–3 μM). We previously reported an alternative mechanism for memantine: an anti-inflammatory effect by reducing the activity of microglia and an increase in the release of neurotrophic factors by astroglia, which are mechanistically remote from an NMDA receptor. We hypothesize that the decline in TNF-α and increase in TGF-β1 levels in the current study were the result of memantine’s anti-inflammatory effect, not its

| Treatment Group | Dropout rate | Adjusted hazard ratio model |
|-----------------|--------------|-----------------------------|
|                 | n/Total n (%) | Exp (B) | p-value |
| Memantine       | 8/45 (15.1)  | 1 (Ref)       |         |
| Placebo         | 17/58 (22.7) | 1.586 | 0.282    |

Table 3. Hazard ratio (HR) of dropout during the trial (n = 25) (Cox proportional hazards model). Exp (B): odds ratio; (Ref): reference group.

| Subscales from side effect checklist | Memantine | Placebo | p-value |
|-------------------------------------|-----------|---------|---------|
| A. Mental Status [mean ± SD]        | 0.14 ± 0.47 | 0.06 ± 0.24 | 0.31     |
| B. Urogenital system [mean ± SD]    | 0.81 ± 0.96 | 0.48 ± 0.85 | 0.07     |
| C. Cardiovascular System [mean ± SD]| 0.02 ± 0.15 | 0.02 ± 0.14 | 0.91     |
| D. Head and neck [mean ± SD]        | 0.21 ± 0.47 | 0.31 ± 0.76 | 0.43     |
| E. Four limbs [mean ± SD]           | 0.07 ± 0.34 | 0.04 ± 0.28 | 0.64     |
| F. Skin [mean ± SD]                 | 0.14 ± 0.35 | 0.17 ± 0.38 | 0.63     |
| G. Gastrointestinal system [mean ± SD]| 0.07 ± 0.34 | 0.04 ± 0.28 | 0.63     |

Table 4. Evaluation of Side effect Checklist at endpoint for opioid-dependent patients taking memantine or a placebo. Score of symptoms: 0 = absent, 1 = mild, 2 = moderate, 3 = severe.
function as an NMDA-receptor blocker. However, current study design did not address this mechanistic concern; additional mechanistic studies are necessary to confirm this hypothesis.

When treating neuropsychiatric disorders, being able to identify and quantify peripheral biomarkers for diagnosis or monitoring treatment response still remains a clinical goal. Some studies have suggested that changes in proinflammatory cytokines and BDNF may be related to the pathophysiology of opioid dependence. In the current study, we found that add-on memantine was no more effective than was placebo for modulating IL-6, IL-8, CRP, and BDNF levels in opioid-dependent patients. Furthermore, memantine was no more effective than was placebo for increasing the retention rate in the trial. Whether memantine can improve the MMT completion rate requires further study. We suspect that 12 weeks may not be long enough to detect other clinical and immunological improvements. At least 6 months of treatment may be needed.

Our study has some limitations. First, we measured plasma cytokines because previous studies suggested that changes in peripheral cytokine secretion might indicate changes in central levels. However, like other studies (e.g.,), we were unable to arrive at a definitive conclusion about this. Second, our study was undoubtedly too short and our study populations too small to confirm our positive findings. Third, the current study support that memantine may decrease does of methadone. However, reduction in dose of methadone not necessarily reflects decrease of methadone tolerance, relief of opioid withdrawal and craving for heroin. We did not use the clinical opiate withdrawal scale (COWS) to measure withdrawal symptoms. These hypotheses need be confirmed with further data collected. Furthermore, if we correct for multiple comparisons, our positive findings for memantine's beneficial effects may not hold up. In addition, we did not explore other factors, such as smoking and weight, which could influence the effects of memantine. Finally, because the present study was a fixed-dose comparison without dose-assessment trials, the definitive effects of add-on memantine and their clinical efficacy require additional studies.

In conclusion, we found that treating opioid-dependent patients undergoing MMT with add-on memantine decreased the methadone dose required, significantly reduced plasma TNF-α levels, and significantly increased TGF-β1 levels, but that it had little effect on other cytokines. Our data support the efficacy of memantine in treating opioid-dependent patients on MMT. We conclude that low-dose memantine might be a feasible adjuvant therapy for attenuating inflammation and inhibiting methadone tolerance.

**References**

1. Mattick, R. P., Breen, C., Kimber, J., Davoli, M., Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. *Cochrane Database Syst. Rev.* 2, CD002207 (2014).
2. Thomas, P. T., Bhargava, H. N., House, R. V., Immunomodulatory effects of in vitro exposure to morphine and its metabolites. *Pharmacology.* 50, 51–62 (1995).
3. Kapasi, A. A., Gibbons, N., Mattana, J., Singhal, P. C., Morphine stimulates mesangial cell TNF-alpha and nitrite production. *Inflammation.* 24, 463–476 (2000).
4. Zubelewicz, B., Muc-Wierzgon, M., Harbuz, M. S., Brodziak, A., Central single and chronic administration of morphine stimulates corticosterone and interleukin (IL)-6 in adjuvant-induced arthritis. *J. Physiol. Pharmacol.* 51, 897–906 (2000).
5. Duyzan, I., Laman, N. E., Histo- and immunocytochemical detection of inducible NOS and TNF-alpha in the locus coeruleus of human opiate addicts. *J. Chem. Neuroanat.* 37, 65–70 (2009).
6. Angelucci, F. et al. Chronic heroin and cocaine abuse is associated with decreased serum concentrations of the nerve growth factor and brain-derived neurotrophic factor. *J. Psychopharmacol.* 21, 820–825 (2007).
7. Graham, D. L. et al. Dynamic BDNF activity in nucleus accumbens with cocaine use increases self-administration and relapse. *Nat. Neurosci.* 10, 1029–1037 (2007).
8. Bolanos, C. A., Nestler, E. J., Neurotrophic mechanisms in drug addiction. *Neuromolecular Med.* 5, 69–83 (2004).
9. Mattick, R. P., Breen, C., Kimber, J., Davoli, M., Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. *Cochrane Database Syst. Rev.* 10.1002/14651858.CD002209.pub2, CD002209 (2009).
10. Mattick, R. P., Kimber, J., Breen, C., Davoli, M., Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. *Cochrane Database Syst. Rev.* 10.1002/14651858.CD002207.pub3, CD002207 (2008).
11. Bruce-Keller, A. J. et al. Morphine causes rapid increases in giall activation and neuronal injury in the striatum of inducible HIV-1 Tat transgenic mice. *Glia.* 56, 1414–1427 (2008).
12. Chen, S. L. et al. Low-dose memantine attenuated morphine addictive behavior through its anti-inflammation and neurotrophic effects in rats. *J. Neuroimmune Pharmacol.* 7, 444–453 (2012).
13. Lee, S. Y. et al. The Effects of Add-On Low-Dose Memantine on Cytokine Levels in Bipolar II Depression: A 12-Week Double-Blind, Randomized Controlled Trial. *J. Clin. Psychopharmacol.* 34, 337–343 (2014).
14. Shergian, S. V. et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. *J. Clin. Psychiatry.* 59 Suppl. 20, 22–33; quiz 34–57 (1998).
15. Endicott, J., Spitzer, R. L., A diagnostic interview: the schedule for affective disorders and schizophrenia. *Arch. Gen. Psychiatry.* 35, 837–844 (1978).
16. Liao, D. L. et al. Higher methadone doses are associated with lower mortality in patients of opioid dependence in Taiwan. *J. Psychiatric Res.* 47, 1530–1534 (2013).
17. D’Amico, T., Pollack, H. A., Frimpong, J. A., Wuchiett, D., Evidence-based treatment for opioid disorders: a 23-year national study of methadone dose levels. *J. Subst. Abuse Treat.* 47, 245–250 (2014).
18. Webster, L. R., Reisfeld, G. M., Dasgupta, N., Eight principles for safer opioid prescribing and cautions with benzodiazepines. *Postgrad. Med.* 127, 27–32 (2015).
19. Shi, J. et al. PET imaging of dopamine transporter and drug craving during methadone maintenance treatment and after prolonged abstinence in heroin users. *Eur. J. Pharmacol.* 579, 160–166 (2008).
20. Mintzer, M. Z., Stitzer, M. L., Cognitive impairment in methadone maintenance patients. *Drug Alcohol Depend.* 67, 41–51 (2002).
21. Prosser, J., London, E. D., Galynker, I., Sustained attention in patients receiving and abstinent following methadone maintenance treatment for opiate dependence: performance and neuroimaging results. *Drug Alcohol Depend.* 104, 228–240 (2009).
22. Yang, Y. C. et al. Transforming growth factor-beta1 in inflammatory airway disease: a key for understanding inflammation and remodeling. Allergy. 67, 1193–1202 (2012).
23. Vaughan, D. E., PAI-1 and TGF-beta: unmasking the real driver of TGF-beta-induced vascular pathology. Arterioscler. Thromb. Vasc. Biol. 26, 679–680 (2006).
24. Redondo, S., Navarro‐Dorado, J., Ramajo, M., Medina, U., Tejerina, T., The complex regulation of TGF-beta in cardiovascular disease. Vasc. Health Risk Manag. 8, 533–539 (2012).
25. Lu, Y. et al. TGFBI genetic polymorphisms and coronary heart disease risk; a meta-analysis. BMC Med. Genet. 13, 39 (2012).
26. Bisaga, A. et al. The NMDA antagonist memantine attenuates the expression of opioid physical dependence in humans. Psychopharmacology (Berl.). 157, 1–10 (2001).
27. Comer, S. D., Sullivan, M. A., Memantine produces modest reductions in heroin-induced subjective responses in human research volunteers. Psychopharmacology (Berl.). 193, 235–245 (2007).
28. Bisaga, A. et al. A placebo controlled trial of memantine as an adjunct to oral naltrexone for opioid dependence. Drug Alcohol Depend. 119, e23–29 (2011).
29. Sani, G. et al. The role of memantine in the treatment of psychiatric disorders other than the dementias: a review of current preclinical and clinical evidence. CNS Drugs. 26, 663–690 (2012).
30. Muhonen, L. H., Lonnqvist, J., Juva, K., Alho, H., Double-blind, randomized comparison of memantine and escitalopram for the treatment of major depressive disorder comorbid with alcohol dependence. J. Clin. Psychiatry. 69, 392–399 (2008).
31. Zdanys, K., Tampi, R. R., A systematic review of off-label uses of memantine for psychiatric disorders. Prog. Neuropsychopharmacol. Biol. Psychiatry. 32, 1362–1374 (2008).
32. Parsons, C. G., Danysz, W., Quack, G., Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist—a review of preclinical data. Neuropharmacology. 38, 735–767 (1999).
33. Wu, H. M. et al. Novel neuroprotective mechanisms of memantine: increase in neurotrophic factor release from astroglia and anti-inflammation by preventing microglial activation. Neuropharmacology. 34, 2344–2357 (2009).
34. Ghazavi, A., Mosayebi, G., Solhi, H., Rafiei, M., Moazzeni, S. M., Serum markers of inflammation and oxidative stress in chronic opium (Taryak) smokers. Immunol. Lett. 153, 22–26 (2013).
35. Ghazavi, A., Solhi, H., Moazzeni, S. M., Rafiei, M., Mosayebi, G., Cytokine profiles in long-term smokers of opium (Taryak). J. Addict. Med. 7, 200–203 (2013).
36. Pan, W., Kastin, A. J., Penetration of neurotrophins and cytokines across the blood-brain/blood-spinal cord barrier. Adv. Drug Deliv. Rev. 36, 291–298 (1999).

Acknowledgments
We thank Dr Liang-Jen Wang for his statistical advice, and Ms Hong-Yi Chang for her assistance in preparing this manuscript. This work was supported in part by grant NSC98-2314-B-006-022-MY3 (to RBL) from the Taiwan National Science Council, grant DOH 95-TD-M-113-055 (to RBL) from the Taiwan Department of Health, grant NHRI-EX-97-9738NI (to RBL) from the Taiwan National Health Research Institute, and the National Cheng Kung University Project for Promoting Academic Excellence and Developing World Class Research Centers.

Author Contributions
S.Y.L. and S.L.C. wrote the first draft. S.Y.L., L.J.W., S.L.C., Y.H.C. and T.Y.W. managed the lab work and statistics. T.Y.W., P.S.C., S.Y.H., N.S.T., I.H.L., K.C.C. and Y.K.Y. managed participant recruitment. R.B.L. and J.S.H. supervised this work and edited the manuscript. All authors reviewed the manuscript.

Additional Information
Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Lee, S.-Y. et al. Low-dose memantine attenuated methadone dose in opioid-dependent patients: a 12-week double-blind randomized controlled trial. Sci. Rep. 5, 10140; doi: 10.1038/srep10140 (2015).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/